12/14/2012

Catalent Pharma Solutions entered into a biosimilars development and manufacturing deal with Japanese firm UMN Pharma and its subsidiary Unigen. The agreement calls for UMN and Unigen, a contract manufacturer, to produce biosimilars using Catalent's GPEx cell lines.

Related Summaries